Earnings Release
Material disclosure
Other Events
Amneal Pharmaceuticals Expects to Exceed 2025 Financial Guidance
Reports Third Quarter 2025 Financial Results
Amended material disclosure
Reports Second Quarter 2025 Financial Results
News, Securities Holder Rights or Indentures, Material Contracts
FY 2025
Q3
Q2
Q1
FY 2024
Certificate
Registration of Securities
SEC Form 25 - Delisting Notification
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Amended Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report